Angiogenesis Laboratory
The Angiogenesis Laboratory has a long-standing interest in the biology of the tumor vasculature. Our research has identified a series of specific and selective molecular markers of tumor blood vessels. These markers can serve as targets for therapy. Currently we are developing vaccines against these targets for the treatment of cancer.
Arjan Griffioen
Group members
Else Huijbers – senior scientist
Karlijn van Loon – scientist
Parvin Akbari – PhD Student
Gabriela Wachholz – PhD student
Lauren Myburgh - PhD student
Xiaolin Wu - PhD student
Joost Koetier - PhD student
Peter Kemper - PhD student
Prachi Jalan - PhD student
Lobke van Bergen - PhD student
Rakesh Ramjiawan - PhD student
Quinty Hansen – technician
Rowan van Heiningen – technician
Emma Bos – technician
Ruby Fillinger – student
Anni Katajamaki – student
Twan Mooijenkind – student
Key publications
The modes of angiogenesis: an updated perspective
Dudley AC, Griffioen AW. Angiogenesis, 26:477-80. doi: 10.1007/s10456-023-09895-4, 2023.
Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy
Van Beijnum JR, Huijbers EJM, van Loon K, Blanas A, Akbari P, Roos A, Wong TJ, Denisov SS, Hackeng TM, Jimenez CR, Nowak-Sliwinska P, Griffioen AW. Nat Commun. 13:2842, 2022.
Cancer Vaccination against Extracellular Vimentin Efficiently Adjuvanted with Montanide ISA 720/CpG
Van Loon K, Huijbers EJM, de Haan JD, Griffioen AW. Cancers 14:2593, 2022.
Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes - PubMed (nih.gov)
Huinen ZR, Huijbers EJM, Van Beijnum JR, Nowak-Sliwinnska P, Griffioen AW. Nat Rev Clin Oncol. 18:527-40, 2021.
Trained Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition
Priem B, Van Leent MMT, Teunissen AJP, Sofias AM, Mourits VP, Willemsen L, Klein ED, Oosterwijk RS, Meerwaldt AE, Munitz J, Prévot G, Verschuur AV, Nauta SA, Van Leeuwen EM, Fisher EL, de Jong KAM, Zhao Y, Toner JC, Soultanidis G, Calgano C, Bomans PHH, Friedrich H, Sommerdijk NAJM, Reiner T, Duivenvoorden R, Zupančič E, Di Martino JS, Kluza E, Rashidian M, Ploegh HL, Dijkhuizen RM, Hak S, Pérez-Medina C, Bravo-Cordero JJ, De Winther MPJ, Joosten LAB, Van Elsas A, Fayad ZA, Rialdi, A, Torre D, Guccione E, Ochando J, Netea MG, Griffioen AW, Mulder WJM. Cell 183:786-801, 2020.
An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature
Huijbers EJM, Van Beijnum JR, Lê CT, Langman S, Nowak-Sliwinska P, Mayo KH, Griffioen AW. Vaccine 36:3054-3060, 2018.
Consensus guidelines for the use and interpretation of angiogenesis assays
Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin, AC, Auerbach R, Augustin HG, Bates DO, Van Beijnum JR, Bender RHF, Bergers G, Bikfalvi, A, Bischoff B, Böck BC, Brooks PC, Bussolino B, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, Van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC and Griffioen AW. Angiogenesis 21:425-532, 2018.
Reply to Marchiò et al.: Antitumor immune regulation by angiostatic therapy
Wentink MQ, Huijbers EJ, Timmerman P and Griffioen AW. Proc.Natl.Acad.Sci USA, 114:E3166-7, 2017.
Contact information
Keywords
Angiogenesis | immunotherapy | vaccines | tumor blood vessels | vascular targeting | anti-angiogenesis